

Special Issue

Hybrid and Chimieric Heterocyclic Compounds as Anticancer and Antimicrobial Agents

Message from the Guest Editor

A literature survey revealed that among heterocycles are privileged scaffolds applicable to the development of new drug entities, exerting a large variety of biological activities, such as anticancer, antiplasmodial and antimalarial, antitubercular, antibacterial, antifungal, antiviral, anthelmintic, anti-HIV, analgesic, anticonvulsant, anti-inflammatory, antihistaminic, antipsychotic, anti-Alzheimer's and antihypertensive actions, among others.

The aim of this Special Issue is to provide a platform for researchers to present the latest developments in anticancer and antimicrobial medicinal chemistry research, focused on biological active hybrid and chimieric heterocycles derivatives.

Guest Editor

Prof. Dr. Ionel Mangalagiu

Chemistry Department, Alexandru Ioan Cuza University of Iasi, 700506 Iasi, Romania

Deadline for manuscript submissions

closed (15 February 2024)



Molecules

an Open Access Journal
by MDPI

Impact Factor 4.6
CiteScore 8.6
Indexed in PubMed



mdpi.com/si/182028

Molecules
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
molecules@mdpi.com

[mdpi.com/journal/
molecules](https://mdpi.com/journal/molecules)





Molecules

an Open Access Journal
by MDPI

Impact Factor 4.6
CiteScore 8.6
Indexed in PubMed



[mdpi.com/journal/
molecules](https://mdpi.com/journal/molecules)



About the Journal

Message from the Editor-in-Chief

As the premier open access journal dedicated to experimental organic chemistry, and now in its 25th year of publication, the papers published in *Molecules* span from classical synthetic methodology to natural product isolation and characterization, as well as physicochemical studies and the applications of these molecules as pharmaceuticals, catalysts and novel materials. Pushing the boundaries of the discipline, we invite papers on multidisciplinary topics bridging biochemistry, biophysics and materials science, as well as timely reviews and topical issues on cutting edge fields in all these areas.

Editor-in-Chief

Prof. Dr. Thomas J. Schmidt

Institute of Pharmaceutical Biology and Phytochemistry, University of Münster, Corrensstrasse 48, D-48149 Münster, Germany

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, MEDLINE, PMC, Reaxys, CaPlus / SciFinder, MarinLit, AGRIS, and other databases.

Journal Rank:

JCR - Q2 (Biochemistry and Molecular Biology) / CiteScore - Q1 (Organic Chemistry)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 16.1 days after submission; acceptance to publication is undertaken in 2.6 days (median values for papers published in this journal in the first half of 2025).